Showing results (861-870 of 977) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|July 20, 2017
Neither epithelial nor mesenchymal circulating tumor cells isolated from breast cancer patients are tumorigenic in NOD-scid Il2rg miceVera S Donnenberg, Alexander Huber, Per Basse, et al.
NPJ Breast Cancer|July 20, 2017
Internet tools to enhance breast cancer careShlomit Strulov Shachar, Hyman B Muss
NPJ Breast Cancer|July 20, 2017
Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaborationSamuel C Y Leung, Torsten O Nielsen, Lila Zabaglo, et al.
NPJ Breast Cancer|July 20, 2017
Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based studyValentina I Petkov, Dave P Miller, Nadia Howlader, et al.
NPJ Breast Cancer|July 20, 2017
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variantsFresia Pareja, Felipe C Geyer, Caterina Marchiò, et al.
NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.
NPJ Breast Cancer|October 26, 2017
Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2- node positive breast cancer-A National Cancer Database studyPrema P Peethambaram, Tanya L Hoskin, Courtney N Day, et al.
NPJ Breast Cancer|November 10, 2017
Erratum: Author Correction: The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer riskThomas P Slavin, Kara N Maxwell, Jenna Lilyquist, et al.
NPJ Breast Cancer|September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Ashish Sanil, et al.
NPJ Breast Cancer|September 14, 2017
Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registrySalomon M Stemmer, Mariana Steiner, Shulamith Rizel, et al.
Pageof 98